实用老年医学

实用老年医学 ›› 2021, Vol. 35 ›› Issue (6): 591-594.doi: 10.3969/j.issn.1003-9198.2021.06.014

• 临床研究 • 上一篇    下一篇

依达拉奉对老年缺血性脑卒中半暗带体积及神经功能缺损程度的影响

陈东丽, 宋丽云, 陈杰, 杨震, 郭敏   

  1. 101318 北京市,北京市顺义区空港医院神经内科(陈东丽,宋丽云,陈杰,杨震);100049 北京市,航天中心医院神经内科(郭敏)
  • 收稿日期:2020-06-20 发布日期:2021-06-29
  • 通讯作者: 郭敏,Email:shfly19@yeah.net
  • 基金资助:
    国家重点研发计划资助项目(2018YFC1705000)

Effects of edaravone on penumbra volume and nervous function deficiency in elderly patients with ischemic stroke

CHEN Dong-li, SONG Li-yun, CHEN Jie, YANG Zhen, GUO Min   

  1. CHEN Dong-li, SONG Li-yun, CHEN Jie, YANG Zhen. Department of Neurology, Beijing Shunyi Airport Hospital, Beijing 101318, China;
    GUO Min. Department of Neurology, Aerospace Center Hospital, Beijing 100049, China
  • Received:2020-06-20 Published:2021-06-29

PDF (PC)

781

摘要： 目的 探究依达拉奉对老年缺血性脑卒中病人的临床疗效及半暗带体积、神经功能缺损程度的影响。方法 回顾性收集2017年6月至2019年6月北京市顺义区空港医院收治的108例老年缺血性脑卒中病人作为研究对象,并依据不同的治疗方案分为对照组和研究组,各54例。对照组接受阿司匹林肠溶片治疗,而研究组则在对照组的基础之上加用依达拉奉治疗。比较2组的治疗效果、NIHSS、格拉斯哥昏迷评分(GCS)、日常生活能力评分(ADL)、凝血功能情况以及T细胞亚群水平,比较2组病人的半暗带体积变化情况。结果 治疗后,研究组有效率优于对照组(P＜0.05),GCS、ADL评分和凝血酶原时间、活化部分凝血活酶时间均高于对照组(P＜0.05);研究组病人CD4+、CD4+/ CD8+水平均高于对照组(P＜0.05),而CD8+水平低于对照组(P＜0.05);研究组NIHSS评分低于对照组(P＜0.05),半暗带体积小于对照组(P＜0.05)。结论 在缺血性脑卒中临床治疗中,加用依达拉奉临床疗效显著,不仅可以改善病人的凝血功能及神经功能、外周血T细胞亚群水平,还可提高病人的日常生活能力,缩小病人的半暗带体积,安全性较高,值得在临床中推广应用。

关键词: 依达拉奉, 缺血性脑卒中, 临床疗效, 老年人

Abstract: Objective To explore the clinical effect of edaravone in the elderly patients with ischemic stroke and the influence on penumbra volume and nervous function deficiency. Methods From June 2017 to June 2019, 108 elderly patients with ischemic stroke who were admitted to the Shunyi Airport Hospital were enrolled in this retrospective study, and they were divided into control group and study group according to different treatment methods, with 54 cases in each group. The control group was treated with aspirin enteric-coated tablets, while the study group was treated with edaravone on the basis of the control group. The efficacy was compared between the two groups. National Institute of Health Stroke Scale (NIHSS) score, Glasgow coma score (GCS) and ability of daily living (ADL) score were evaluated, and the levels of coagulation function, T cell subsets and penumbra volume were detected and compared between the two groups. Results After treatment, the scores of GCS and ADL, and the levels of prothrombin time (PT) and activated partial thromboplastin time (APTT) in the study group were higher than those in the control group (P＜0.05). The levels of CD4+ and CD4+/ CD8+ in the study group were higher than those in the control group (P＜0.05), while the level of CD8+ was lower than that in the control group (P＜0.05). The NIHSS score of the study group was lower than that of the control group (P＜0.05), and the penumbra volume of the study group was smaller than that of the control group (P＜0.05). Conclusions Edaravone shows significant clinical effect in the treatment for ischemic stroke. It can not only improve the patients′ blood coagulation function, neurological function, and peripheral blood T cell subsets, but also improve the patients′ ADL.

Key words: edaravone, ischemic stroke, efficacy, aged

中图分类号: